High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.
Researchers outlined risks, mechanisms, and possible strategies related to cardiovascular toxicity with proteasome inhibitors for multiple myeloma therapy.
What are some of the most important factors affecting outcomes in patients with multiple myeloma?
Researchers sought to determine if vagal nerve activity could predict overall survival and progression-free survival in patients with R/R DLBCL and MM, respectively.
Researchers sought to determine whether conversion of MRD status during maintenance would affect risk of disease progression in patients with MM.
Ide-cel significantly improves progression-free survival and response compared with standard regimens.
Researchers sought to determine whether elotuzumab with pomalidomide and dexamethasone would improve survival in relapsed/refractory multiple myeloma.
Researchers sought to confirm the safety and efficacy of idecabtagene vicleucel in a real-world population of patients with relapsed/refractory multiple myeloma.
Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.
Decreased survival seen for both underweight and severe obesity in newly diagnosed patients.
